(Q36057298)

11 August 2017

Cost-effectiveness of using human papillomavirus 16/18 genotype triage in cervical cancer screening (English)

1 reference

11 August 2017

human papillomavirus 16

1 reference

based on heuristic

inferred from title

cervix uterine cancer

1 reference

Arthi Vijayaraghavan

1

1 reference

11 August 2017

Molly B Efrusy

2

1 reference

11 August 2017

Karyn A Goodman

3

1 reference

11 August 2017

Christopher C Santas

4

1 reference

11 August 2017

Warner K Huh

5

1 reference

11 August 2017

language of work or name

English

0 references

publication date

14 August 2010

1 reference

11 August 2017

1 reference

11 August 2017

119

1 reference

11 August 2017

2

1 reference

11 August 2017

237-242

1 reference

Detection of precancerous cervical lesions is differential by human papillomavirus type

11 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4568837

Human papillomavirus genotype distributions: implications for vaccination and cancer screening in the United States

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4568837

New technologies in cervical cancer screening

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4568837

Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4568837

Human papillomavirus infection and the primary and secondary prevention of cervical cancer.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4568837

Cervical cancer screening following prophylactic human papillomavirus vaccination

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4568837

Cost-effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16,18 vaccination

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4568837

The potential utility of HPV genotyping in screening and clinical management

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4568837

Human papillomavirus and Papanicolaou tests to screen for cervical cancer

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4568837

2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4568837

2006 consensus guidelines for the management of women with cervical intraepithelial neoplasia or adenocarcinoma in situ

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4568837

Chapter 19: Cost-effectiveness of cervical cancer screening

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4568837

The probability for a Pap test to be abnormal is directly proportional to HPV viral load: results from a Swiss study comparing HPV testing and liquid-based cytology to detect cervical cancer precursors in 13,842 women

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4568837

Epidemiologic classification of human papillomavirus types associated with cervical cancer

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4568837

Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4568837

Cost-effectiveness of a potential vaccine for human papillomavirus

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4568837

Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4568837

Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4568837

Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test.

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4568837

Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer.

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4568837

Cervical cancer incidence in a prevaccine era in the United States, 1998-2002.

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4568837

The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice.

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4568837

Human papillomavirus infection and time to progression and regression of cervical intraepithelial neoplasia

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4568837

Natural history of cervicovaginal papillomavirus infection in young women.

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4568837

Overview of the European and North American studies on HPV testing in primary cervical cancer screening

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4568837

Cost effectiveness of high-risk HPV DNA testing for cervical cancer screening in South Africa

21 October 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.07.004

Epidemiologic profile of type-specific human papillomavirus infection and cervical neoplasia in Guanacaste, Costa Rica

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.07.004

Type-specific duration of human papillomavirus infection: implications for human papillomavirus screening and vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.07.004

Cervical cancer: prevention, diagnosis, and therapeutics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.07.004

Tumor size, irradiation dose, and long-term outcome of carcinoma of uterine cervix

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.07.004

2006 consensus guidelines for the management of women with abnormal cervical screening tests

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.07.004

2006 consensus guidelines for the management of women with cervical intraepithelial neoplasia or adenocarcinoma in situ.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.07.004

HPV screening for cervical cancer in rural India

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.07.004

Cost-effectiveness of alternative triage strategies for atypical squamous cells of undetermined significance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.07.004

Cost-effectiveness of human papillomavirus DNA testing for cervical cancer screening in women aged 30 years or more.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.07.004

Modeling cervical cancer prevention in developed countries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.07.004

Integration of human papillomavirus vaccination, cytology, and human papillomavirus testing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.07.004

What is the role of HPV typing in the United States now and in the next five years in a vaccinated population?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.07.004

Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial

7 January 2021

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20713299

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Human papillomavirus testing for primary screening of cervical cancer precursors

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20713299

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1016/J.YGYNO.2010.07.004

1 reference

11 August 2017

1 reference

11 August 2017

1 reference